Trials / Completed
CompletedNCT00458146
A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis
A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 60mg of MM-093 Versus Placebo in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Merrimack Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether MM-093 is safe and effective in the treatment of RA.
Detailed description
To evaluate the safety and tolerability of 60 mg of MM-093 in patients who have active RA despite MTX background therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MM-093 | 60mg MM-093/week as a subcutaneous injection for 3 months |
Timeline
- Start date
- 2007-02-01
- First posted
- 2007-04-09
- Last updated
- 2008-03-27
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00458146. Inclusion in this directory is not an endorsement.